Skip to Content

Ferriprox FDA Approval History

FDA Approved: Yes (First approved October 14, 2011)
Brand name: Ferriprox
Generic name: deferiprone
Dosage form: Tablets and Oral Solution
Company: ApoPharma Inc.
Treatment for: Thalassemia, Iron Overload

Ferriprox (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

Development Timeline for Ferriprox

DateArticle
May 21, 2020Approval Chiesi Group Receives FDA Approval for Ferriprox (deferiprone) Twice-a-Day Tablets
Oct 14, 2011Approval FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Sep 14, 2011ApoPharma Announces FDA Advisory Committee Recommendation in Favor of Ferriprox (deferiprone) Approval

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.